MAGNA Hosts 3rd Annual Equity Upfront™ Focused on Maximizing for Optimal Outcomes
Industry-Leading initiative continues to provide opportunities for clients and agencies to engage with diversely-owned media…
Industry-Leading initiative continues to provide opportunities for clients and agencies to engage with diversely-owned media…
Industry-Leading initiative continues to provide opportunities for clients and agencies to engage with diversely-owned media…
New Solution Offers Unmatched Backup and Recovery for Power BI Users COPENHAGEN, DENMARK – February…
Award further establishes STACK as prominent safety innovator in the digital infrastructure industry Denver, COLORADO…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Qualigen Therapeutics, Inc. (“Qualigen” or “the Company,”…
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
BASKING RIDGE, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — Lisata Therapeutics, Inc. (Nasdaq: LSTA) (“Lisata”…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
CARLSBAD, Calif., Feb. 01, 2023 (GLOBE NEWSWIRE) — Pardes Biosciences, Inc. (NASDAQ: PRDS), a clinical-stage…
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Glen Rock, N.J., Feb. 01, 2023 (GLOBE NEWSWIRE) — RespireRx Pharmaceuticals Inc. (OTC Markets: RSPI)…
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
Bagsværd, Denmark, 1 February 2023 – Novo Nordisk A/S has filed its Annual Report 2022…
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
FDA Agrees to Extended Milestones for Long-Term Twirla® Safety Study New Publication Supports Eventual Pursuit…
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
BOSTON, Feb. 01, 2023 (GLOBE NEWSWIRE) — Cue Biopharma, Inc. (Nasdaq: CUE), a clinical-stage biopharmaceutical company…
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…
SAN DIEGO, Feb. 01, 2023 (GLOBE NEWSWIRE) — Recludix Pharma, a leader in platform approaches…